BidaskClub downgraded shares of Intersect ENT (NASDAQ:XENT) from a strong-buy rating to a buy rating in a report released on Friday morning.

A number of other equities analysts have also commented on XENT. Zacks Investment Research raised shares of Intersect ENT from a sell rating to a hold rating in a research note on Wednesday, February 28th. Guggenheim reiterated a buy rating on shares of Intersect ENT in a research report on Thursday, March 1st. ValuEngine upgraded shares of Intersect ENT from a hold rating to a buy rating in a research report on Monday, April 2nd. Berenberg Bank started coverage on shares of Intersect ENT in a research report on Friday, April 20th. They issued a buy rating for the company. Finally, JPMorgan Chase & Co. reiterated an overweight rating and issued a $48.00 target price on shares of Intersect ENT in a research report on Wednesday, May 2nd. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $38.50.

Intersect ENT stock opened at $36.20 on Friday. Intersect ENT has a 52 week low of $25.95 and a 52 week high of $42.95. The company has a market capitalization of $1.12 billion, a P/E ratio of -64.64 and a beta of 0.76.

Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings data on Tuesday, May 1st. The medical equipment provider reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. Intersect ENT had a negative net margin of 15.73% and a negative return on equity of 13.67%. The firm had revenue of $24.70 million during the quarter, compared to analyst estimates of $23.66 million. During the same quarter last year, the business posted ($0.23) EPS. The company’s revenue was up 20.5% on a year-over-year basis. analysts forecast that Intersect ENT will post -0.64 earnings per share for the current fiscal year.

In other news, insider Lisa D. Earnhardt sold 15,000 shares of the firm’s stock in a transaction on Monday, April 16th. The shares were sold at an average price of $39.59, for a total transaction of $593,850.00. Following the transaction, the insider now owns 499,683 shares in the company, valued at approximately $19,782,449.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jeryl L. Hilleman sold 12,833 shares of the firm’s stock in a transaction on Tuesday, June 5th. The shares were sold at an average price of $41.70, for a total transaction of $535,136.10. Following the transaction, the chief financial officer now owns 36,265 shares in the company, valued at approximately $1,512,250.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 53,499 shares of company stock valued at $2,124,827. Insiders own 5.90% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in shares of Intersect ENT during the 1st quarter valued at $132,000. Bank of Montreal Can bought a new position in shares of Intersect ENT during the 4th quarter valued at $135,000. UBS Group AG raised its holdings in shares of Intersect ENT by 81.1% during the 1st quarter. UBS Group AG now owns 4,679 shares of the medical equipment provider’s stock valued at $184,000 after purchasing an additional 2,096 shares in the last quarter. Aperio Group LLC bought a new position in shares of Intersect ENT during the 1st quarter valued at $213,000. Finally, All Terrain Financial Advisors LLC bought a new position in shares of Intersect ENT during the 1st quarter valued at $241,000. Institutional investors and hedge funds own 88.74% of the company’s stock.

Intersect ENT Company Profile

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Analyst Recommendations for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.